The company has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent application entitled “Antigen Specific Multi Epitope Vaccines.
Vaxil said the patent would make it the Canadian leader in respect to using MUC1 signal peptide domains as cancer immunotherapy treatments.
MUC1 is known to be a highly important cancer target, given its therapeutic function, immunogencity, and wide presence in many cancer types.
Many vaccines against cancer target entire cancer antigens – molecules capable of inducing an immune response in the host – whereas Vaxil has developed its proprietary immunotherapy platform for producing cancer vaccines that are more efficient.
In essence, the vaccines produced are relevant to specific signal peptide domains within the cancer antigen.
Vaxil said the patent allowance from the CIPO protects its ownership in Canada of the development of all signal peptides of the MUC1 cancer target.
Vaxil's lead product, the ImMucin cancer vaccine, represents one such promising variation of MUC1's signal peptide. The decision from the CIPO effectively makes Vaxil the only company in Canada that is able to use MUC1 signal peptides as cancer immunotherapies.
ImMucin is an immunotherapeutic treatment that educates a cancer patient's immune system to attack cancer cells via a specified domain, termed signal peptide, of the MUC1 cancer antigen.
“Despite notable recent advances in the treatment of cancer in general and multiple myeloma (MM) in particular, there are still no options resulting in full recovery from the disease. There is a real need for drugs which can delay the recurrence of the disease. ImMucin is intended to meet this need in MM patients with 'minimal residual disease,' turning their cancer into a manageable disease. In light of the clinical results achieved thus far with ImMucin, manifested by a strong diversified immune response, ImMucin has great therapeutic and economic potential,” Dr Carmon said.
Dr Carmen said the patent decision gives the company flexibility in terms of licensing MUC1 signal peptides aside from the 21-mer ImMucin cancer vaccine used in lead product.
“It is an exciting addition to our existing patent portfolio and strengthens our ability to protect our proprietary technologies, and hopefully, follow-on technologies. The patent is expected to also cover other attractive applications for the use of signal peptide domains; in particular, its use for T-cell based cell-therapy," Dr Carmen added.
Speaking to Proactive Investors, executive director Isaac Maresky said: “Vaxil is excited particularly about the broad coverage pertaining to all Signal Peptide Domains of the renowned MUC1 antigen. In a national cancer institute study ranking all cancer targets by importance in treatments, MUC1 was ranked number two of their top 175.”